Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04052178
Other study ID # FIS2014
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 10, 2016
Est. completion date December 21, 2018

Study information

Verified date August 2019
Source Hospital de Mataró
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study design: Multicenter, experimental, randomized, crossed, double blind study (patient and results analysis).

Aim: To evaluate the effect of different neurostimulation techniques on the neurophysiological and biomechanical swallowing mechanisms of patients with dysphagia associated with chronic stroke and select those techniques with the best results to be evaluated in the second phase of the study (medium-term effects).

Outcome measures:

- Videofluoroscopy: prevalence of impaired efficacy and safety of swallow (penetrations and aspirations), penetration aspiration scale (PAS: from 0 to 8), biomechanical parameters (time to laryngeal vestibule closure, upper esophageal sphincter opening).

- Pharyngeal sensory evoked potentials (pSEP): latency and amplitude of obtained evoked potentials. Higher latency (0 onwards) means worse outcome and higher amplitude (0 onwards) means better outcome.

- Pharyngeal motor evoked potentials (pMEP): latency, amplitude, duration and area of obtained evoked potentials. Higher latency (0 onwards) means worse outcome and higher amplitude (0 onwards) means better outcome.

Treatments and patients: 36 post-stroke patients with oropharyngeal dysphagia (PAS superior or equal to 2) randomized patients in 3 treatment arms (3 groups of 12 patients).

- Active and sham repetitive transcranial magnetic stimulation (rTMS): 90% of the resting motor threshold, 1250 pulses, 5 Hz.

- Active and sham Intrapharyngeal Electrical Stimulation (PES): 75% of tolerance threshold, pulses of 0.2 ms, 5 Hz, 10 min.

- Oral Capsaicin (active intervention, 10-5M, TRPV1 agonist) and placebo solution (sham): 100 mL, single administration.

Administration of study therapies:

The study will be performed in two visits separated for one week. In each visit patients will randomly receive active or sham treatment and a pre-post evaluation of biomechanics of deglutition (with VFS) and neurophysiological mechanisms (swallowing afferent and efferent pathways) will be performed in each visit.

Acute randomized administration -> 1 active session (pre/post evaluation with VFS/pSEP/pMEP) + 1 separate control session 1 week apart (pre/post evaluation with VFS/pSEP/pMEP).


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 21, 2018
Est. primary completion date December 21, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients older than 18 years.

- Patients with a diagnosis of stroke of more than 3 months of evolution.

- Patients with clinical signs of dysphagia according to the volume viscosity swallowing test (V-VST).

- Patients capable of complying with the study protocol.

- Explained study and signed informed consent.

Exclusion Criteria:

- History of severe neurodegenerative, digestive diseases, epilepsy or previous seizures.

- Pacemaker or implanted defibrillator carriers.

- Implanted electrode carriers or other stimulation systems.

- Implant carriers or metal plates on the head or neck.

- Cochlear implant carriers.

- Medication pump carriers.

- History of hearing loss associated with noise.

- Cardiopulmonary instability.

- Oropharyngeal dysphagia of structural causes.

- History of head and neck surgery.

- Alcohol or drug dependence.

- Pregnancy or breastfeeding.

- Participate or have participated in another clinical interventionist trial in the 4 weeks prior to inclusion.

Study Design


Intervention

Device:
rTMS active and sham
Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
PES active and sham
Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
Dietary Supplement:
Capsaicin active and placebo
Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hospital de Mataró

Outcome

Type Measure Description Time frame Safety issue
Primary Pharyngeal motor evoked potential (pMEP): latency and amplitude Study the magnitude of the effect by calculating the change of the evoked potential from baseline immediately after the application of the intervention produced by the different treatments. This will be examined and compared between active and sham intervention. The event wil be assessed with pMEP immediately after the application of the intervention (time frame maximum up to 2 hours).
Primary Pharyngeal sensory evoked potential (pSEP): latency and amplitude Study the magnitude of the effect by calculating the change of the evoked potential from baseline immediately after the application of the intervention produced by the different treatments. This will be examined and compared between active and sham intervention. The event wil be assessed with pSEPs immediately after the application of the intervention (time frame maximum up to 2 hours).
Primary Penetration-aspiration scale (PAS) score Study the magnitude of the effect by calculating the change on the prevalence of unsafe swallow (PAS=2) in videofluoroscopy (VFS) from baseline immediately after the application of the intervention. This will be examined and compared between active and sham intervention. The event wil be assessed with the PAS score immediately after the application of the intervention (time frame maximum up to 2 hours from first assessment).
Secondary Opening and closing time of the laryngeal vestibule Time of the laryngeal vestibule opening and closure ranges from 0 to 1000 ms. The event wil be assessed with VFS immediately after the application of the intervention (time frame maximum up to 2 hours from first assessment).
Secondary Prevalence of pharyngeal residue The presence of pharyngeal residue in individual subjects will be assessed. The event will be assessed with VFS immediately after the application of the intervention (time frame maximum up to 2 hours from first assessment).
Secondary Resting motor threshold (RMT) of the pharyngeal cortex RMT is defined as the stimulation intensity in which the half of the stimuli are able to evoke a motor evoked potential of al least 10 uV of amplitude. The event wil be assessed with TMS immediately after the application of the intervention (time frame maximum up to 2 hours from first assessment).
Secondary Pharyngeal sensory thresholds First perception and tolerance thresholds (from 0 to 100 mA) to electrical stimulation of the pharynx will be assessed by asking subjects the exact moment of first perception of the stimulus and the moment in which stimulation is not further tolerated, respectively. The event wil be assessed with pharyngeal electrical stimulation immediately after the application of the intervention (time frame maximum up to 2 hours from first assessment).
Secondary Incidence of Treatment-Emergent Adverse Events Seizures are the most feared side effect associated with transcranial magnetic stimulation (TMS). Seizures are a rare side event during and/or subsequent to a TMS session (1.4%, Bae et al., 2007) commonly not occurring beyond a few days after the last session. No other major or significant side effects are expected associated with the interventions. Although its occurrence is early after the TMS session, seizures and other side effects will be monitored up to 3 months after the intervention.
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05993221 - Deconstructing Post Stroke Hemiparesis